Company intelligence / Profile preview

CovX

San Diego, California, USAcovxlabs.com ↗

Ownership: Private
Employees: ~100
Development stage: Preclinical

Overview

At the time of its acquisition by Pfizer in late 2007/early 2008, CovX had three early-stage compounds—one for diabetes and two for cancer. The most advanced candidate was CVX‑045 (antiangiogenic), which entered Phase I trials for cancer. Another oncology program targeted Angiopoietin‑2 with CVX‑060. A diabetes program called CVX‑096 was expected to enter Phase I. Some programs were discontinued or remained preclinical after the acquisition; none reached commercialization before the unit's closure.

Therapeutic areas: OncologyMetabolic Disorders
Modalities: Peptide-antibody fusion therapeutics ("peptibodies")
Industry: Biotech

Partnerships

Scripps Research Institute licensed foundational antibody discovery technology used by Covx; Scripps received royalties from any resulting therapies.

Beyond the preview

Go deeper on CovX.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CovX.

Explore the full profile